Thandeka Gwete-Moyo

Johannesburg, GT, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease.

Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease.

Journal: The Journal of infection

Published: October 28, 2025

Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages.

Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages.

Journal: Structure (London, England : 1993)

Published: September 29, 2025

Transplacental transferred anti-SARS-CoV-2 neutralizing antibodies in unvaccinated pregnant women in Cameroon occurred during the COVID-19 pandemic, but not in the pre-pandemic period.

Transplacental transferred anti-SARS-CoV-2 neutralizing antibodies in unvaccinated pregnant women in Cameroon occurred during the COVID-19 pandemic, but not in the pre-pandemic period.

Journal: Frontiers in immunology

Published: May 13, 2025

Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.

Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.

Journal: The lancet. HIV

Published: May 12, 2025

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.

Journal: Journal of virology

Published: January 16, 2025

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

Journal: Scientific reports

Published: November 13, 2024

Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.

Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.

Journal: Communications medicine

Published: August 27, 2024

Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.

Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.

Journal: Vaccine

Published: August 18, 2024

Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.

Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.

Journal: Vaccines

Published: July 15, 2024

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Journal: PLOS global public health

Published: June 02, 2024

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Journal: PLOS global public health

Published: December 04, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026